Nomura Holdings Inc. Sells 41,687 Shares of Masimo Co. (NASDAQ:MASI)

Nomura Holdings Inc. trimmed its stake in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 87.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,897 shares of the medical equipment provider's stock after selling 41,687 shares during the quarter. Nomura Holdings Inc.'s holdings in Masimo were worth $975,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in MASI. Barclays PLC boosted its position in Masimo by 152.6% during the third quarter. Barclays PLC now owns 39,957 shares of the medical equipment provider's stock worth $5,329,000 after purchasing an additional 24,137 shares during the period. Trust Co. of Vermont bought a new stake in shares of Masimo in the fourth quarter valued at about $33,000. HB Wealth Management LLC bought a new stake in shares of Masimo in the fourth quarter valued at about $201,000. UMB Bank n.a. boosted its position in shares of Masimo by 180.9% in the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider's stock valued at $32,000 after acquiring an additional 123 shares during the period. Finally, Nisa Investment Advisors LLC boosted its position in shares of Masimo by 16,740.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 5,052 shares of the medical equipment provider's stock valued at $835,000 after acquiring an additional 5,022 shares during the period. 85.96% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of Masimo in a research report on Thursday, April 10th. Raymond James cut their price objective on shares of Masimo from $204.00 to $185.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Piper Sandler reaffirmed an "overweight" rating and set a $200.00 price objective (down previously from $215.00) on shares of Masimo in a research report on Wednesday, May 7th. Wells Fargo & Company cut their price objective on shares of Masimo from $205.00 to $190.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Finally, BTIG Research set a $193.00 price objective on shares of Masimo and gave the stock a "buy" rating in a research report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $191.60.

Masimo Price Performance

NASDAQ MASI traded up $0.22 during trading on Friday, hitting $150.13. 311,070 shares of the company's stock were exchanged, compared to its average volume of 651,566. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The company has a market cap of $8.14 billion, a PE ratio of 103.54 and a beta of 1.23. Masimo Co. has a fifty-two week low of $101.61 and a fifty-two week high of $194.88. The stock's 50 day moving average price is $158.42 and its two-hundred day moving average price is $167.42.

Masimo (NASDAQ:MASI - Get Free Report) last issued its earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 EPS for the quarter, topping the consensus estimate of $1.24 by $0.12. The firm had revenue of $372.00 million during the quarter, compared to the consensus estimate of $367.79 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business's quarterly revenue was down 24.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.77 earnings per share. Research analysts expect that Masimo Co. will post 4.1 EPS for the current year.

Insider Activity

In other news, Director Craig B. Reynolds sold 2,053 shares of the company's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the transaction, the director now owns 16,581 shares of the company's stock, valued at $2,754,601.53. This represents a 11.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Bilal Muhsin sold 10,000 shares of the company's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $163.28, for a total value of $1,632,800.00. Following the completion of the transaction, the chief operating officer now directly owns 24,172 shares of the company's stock, valued at $3,946,804.16. This represents a 29.26% decrease in their position. The disclosure for this sale can be found here. Insiders sold 42,053 shares of company stock valued at $6,998,565 over the last quarter. 16.90% of the stock is owned by company insiders.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.